Seeking trifecta against kidney disease, biotech team lines up $150 million IPO

They built and sold Ilypsa and Relypsa, now this team is prepping their latest company to ask the FDA to approve another drug for chronic kidney disease patients.

Source: bizjournals.com Health Care:Biotechnology headlines - June 5, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news